Team | Fusion Genomics Corp.

John Seminerio, Board Chair

John Seminerio is a serial entrepreneur known for co-founding several successful companies. He co-founded OctigaBay Systems in 2001, which pioneered a new supercomputer platform and was acquired by Cray Inc. in 2004 for $155 million, after securing $24 million in seed financing. Before that, he co-founded Abatis Systems Corporation, a telecommunications vendor acquired by Redback Networks for $1.3 billion in 2000. In 2013, he co-founded PHEMI Systems Corporation, where he served as Board Chair until 2017 and is now an Advisor.

Mohammad Qadir, President & Chief Scientific Officer

Dr Qadir’s training is in genetics and molecular biology. Dr Qadir has over 17 years of research experience. The last ten were at the British Columbia Cancer Agency where he worked with world-renowned experts in genomics and drug development. Dr Qadir is the co-inventor of the CHILDSeq-Sarcoma assay and CHILDDecode (part of FUSIONCloud™). Dr Qadir oversees all the scientific aspects of research and development efforts at FUSION GENOMICS and also serves as the interface for all collaborators.

Greg Stazyk, Chief Technical Officer

Mr Greg Stazyk has over 20 years of experience in senior positions in the IT industry, including senior manager at PMC-Sierra Inc. where he was responsible for its global computer systems operation. Mr. Stazyk was the IT lead for one of Canada’s largest bioinformatics computing platforms at the BC Cancer Agency’s Genome Sciences Centre. Here, he oversaw the expansion of their computing infrastructure from a few dozen core-machines to over 10,000 in the core cluster and over 7 Petabyte of redundant storage in a CAP/CLIA certified environment. Mr Stazyk brings

insight and expertise in IT project management, especially in areas of business fault tolerance and secure storage systems, which are critical for fulfilling FUSION GENOMICS’ cloud computing needs.

WhatsApp Image 2024-05-22 at 15.58.12_b6328f02

Dr. Sepideh Massoumi Alamouti

Dr. Sepideh Massoumi Alamouti is a highly accomplished computational microbiologist with over 17 years of experience in both academic and industrial settings. She is an innovator in developing sophisticated computational platforms and data analysis models aimed at the detection and identification of human pathogens. Since 2016, she has played a pivotal role in the design and development of the ONETestTM platform and its validation across a diverse range of bacterial and viral pathogens. Dr. Massoumi Alamouti earned her Ph.D. in Microbiology at the

University of British Columbia, supported by an NSERC scholarship. Her extensive contributions to microbial and cancer genomics have resulted in the publication of over 20 scientific papers in esteemed journals, including PNAS, Molecular Ecology, and Blood.

Brian Kwok, VP of Product DevelopmentMr Kwok is a graduate of the molecular biology and biochemistry program at Simon Fraser University and trained at the BC Cancer Agency’s Genome Sciences Centre. Mr.Kwok has 10 years of experience in molecular biology and genomic technologies including leading edge Next Generation Sequencing (NGS). Mr. Kwok worked at the Koninklijk Instituut voor de Tropen (KIT), also known as The Royal Tropical Institute in the Netherlands, where he was actively involved in developing molecular diagnostic assays for the identification of drug-

resistant tuberculosis. Mr. Kwok has worked in combinatorial drug screening and led the development of the CHILDSeq-Sarcoma assay. He is responsible for the development, testing, and production of FUSION’s new assays.

Livleen, Chief Financial Officer

Livleen is the former CEO of bioLytical Laboratories, an infectious disease rapid diagnostic test manufacturer where she scaled the company from 50 to over 110 employees, achieved 4x revenue growth, double digit EBITDA %, and turned sustainably profitable.

Prior to joining bioLytical, Livleen was the Head of Finance and Operations at Luvo Foods where she helped raise $45M and launch 34 USDA approved products with 5,500 retailers in the US.

She joined the biotech industry in 2006, holding management positions before rising to the position of Chief Financial Officer for Response Biomedical, a medical device manufacturer, which was publicly traded at the time, and where Livleen supported the CEO in raising $38M.

Livleen earned her designation as a Certified Management Accountant in 2001 and is a Chartered Professional Accountant.